Anti-Cancer Drugs · 2015 · 19 citations · 18 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyGenitourinary OncologyBladder CancerGenitourinary Cancer PharmacotherapyClinical RemissionEastern Cooperative Oncology Group Performance StatusIntention-to-treat AnalogsSecond RemissionSecond-line ChemotherapyStable Disease AssessmentUnmet Health NeedUrothelial Carcinoma Systemic Therapy
Relapsed urothelial cancer represents an unmet medical need. Vinflunine is a third-generation antimicrotubuline inhibitor and is currently the only approved drug for second-line treatment across the European Union. We conducted a retrospective analysis assessing the efficacy and safety of vinflunine in 71 Greek patients with relapsed urothelial cancer who were treated between 2005 and 2014. An overall 84% of our patients received vinflunine as second-line treatment, 77% had a performance status of Eastern Cooperative Oncology Group scale 0 or 1, and 30% had liver metastasis at the time of vinflunine administration. A median of four cycles of vinflunine were administered (range 1-16). The most common reported adverse events were constipation, fatigue, and anemia. Median progression-free survival was 6.2 months (95% confidence interval: 4.4-8.8) and overall survival was 11.9 months (95% confidence interval: 7.4-21). Two patients (3%) achieved a complete remission, seven a partial remission (10%), and 22 (31%) had stable disease according to an intention-to-treat analysis. Hemoglobin level less than 10 g/dl and Eastern Cooperative Oncology Group performance status greater than 1 were independent adverse prognostic factors. Stratification according to the Bellmunt risk model was also associated with progression-free survival and overall survival in our population. Vinflunine appears to be a safe and effective treatment modality for relapsed urothelial cancer. More effective therapies and more accurate prognostic algorithms should be sought.
18
Hans von der Maase, Steen Werner Hansen, J.T. Roberts et al. · Journal of Clinical Oncology · 2000 · 2.3K citations · Full text
Medicine, Oncology, Pharmacology +11
Joaquim Bellmunt, Christine Théodore, T. Demkov et al. · Journal of Clinical Oncology · 2009 · 779 citations · Full text
Medicine, Oncology, Pharmacotherapy +10
Joaquim Bellmunt, Toni K. Choueiri, Ronan Fougeray et al. · Journal of Clinical Oncology · 2010 · 454 citations
Medicine, Oncology, Chemotherapy +11